AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01077713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60mg/m2 on day 1 of each 3 week cycle
Study NCT01077713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200mg/m2 on days 1-8 of each 3 week cycle
Study NCT01077713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 on days 1-8 of each 3 week cycle
Study NCT05245981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRI.MAG 2
Description: Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
Study NCT03718156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREPARED Trial Intervention
Description: Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
Study NCT00736528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 05 mg BID for 14 days
Study NCT00736528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 15 mg BID for 14 days
Study NCT00736528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 45mg BID for 14 days
Study NCT00736528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14 days
Study NCT00467584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Aspirin (1300 mg/day)
Description: 1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
Study NCT00467584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Aspirin (162 mg/day)
Description: 162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
Study NCT00467584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
Study NCT02762565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEFS system (Product Name: Intelligent Breast Exam™ or iBE™
Study NCT02579083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB66
Description: 10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
Study NCT02579083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
Study NCT06224582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinxingmihuan oral solution
Description: Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
Study NCT06224582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
Study NCT00685971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5000 IU of cholecalciferol
Description: 5 drops taken once daily for 12 weeks
Study NCT00685971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 drops once daily for 12 weeks
Study NCT02947113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
Study NCT02947113 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
Study NCT02947113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
Study NCT02947113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
Study NCT05494554 — intervention group
Intervention type: DEVICE
Intervention: Changing mechanical ventilation mode
Description: On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
Study NCT01478633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
Study NCT01313728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone plus Tretinoin Gel
Description: Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
Study NCT01313728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin Gel
Description: Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
Study NCT00581594 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Graft-augmented colporrhaphy
Description: Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
Study NCT00581594 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional posterior colporrhaphy
Description: Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
Study NCT02678221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Study NCT02678221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02678221 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Study NCT03158337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT00467818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
Study NCT00467818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage as that of omega 3 fatty acids
Study NCT06776276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi exercises
Description: Tai-chi (TC) is a kind of CAM Qigong exercises, is a type of classic Chinese martial arts. It entails deliberate, slow-motion physical movements that are done alongside inward concentration, awareness of breathing, and the inherent power or energy in the body. It promotes general purposes of health and spirituality. It is generally accessible and offered to older people in public places.
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcraniel Magnetic Stimulation active and sham
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Transcraniel Magnetic Stimulation active and sham
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: active Transcranial Magnetic Stimulation
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: active Transcranial Magnetic Stimulation
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: daily for three weeks
Study NCT00149071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: daily for three weeks
Study NCT00574301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Removal and Margin Ablation
Description: Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
Study NCT03404206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 220 mg x 2 tablets, oral, single dose
Study NCT03404206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (Advil)
Description: 200 mg x 2 tablets, oral, single dose
Study NCT03404206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 2 tablets, oral, single dose
Study NCT02756000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
Study NCT02756000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
Study NCT02756000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dobutamine stress echocardiography
Description: Echocardiographic stress test of provoked myocardial ischemia using dobutamine
Study NCT02280421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151 400mg + 100mg ciclosporin
Study NCT02280421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151 1200mg + 100mg ciclosporin
Study NCT03275701 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triumeq
Description: Open Label, Switch to Triumeq (ABC/DTG/3TC)
Study NCT03712969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenlingcao Oral Liquid
Description: Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
Study NCT01193517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
Study NCT01193517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
Study NCT01193517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
Study NCT01193517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine MTD
Description: Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
Study NCT04522414 — intervention group
Intervention type: OTHER
Intervention: cries longitudinally registered
Description: Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
Study NCT01360450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine HCL
Description: At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between \< 9.
Study NCT01360450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
Study NCT02115256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Terbutaline
Description: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
Study NCT02115256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nitroglycerine
Description: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Study NCT02307409 — intervention group
Intervention type: OTHER
Intervention: Sonoclot/TEG test
Description: The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
Study NCT00146770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme
Description: Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
Study NCT00146770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme
Description: 0.58 mg/kg Aldurazyme every week for 208 weeks
Study NCT00146770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo for 26 weeks
Study NCT04895618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia GVL
Description: Single treatment with the Erchonia GVL to the neck and shoulders. The treatment applies 520 nanometers (nm) green diode light and 405 nm violet diode light simultaneously.
Study NCT00617435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vaccenic acid enriched diet
Description: The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil.
Study NCT00617435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elaidic acid enriched diet
Description: Mixture of vegetable oils (including partially hydrogenated oils)
Study NCT00617435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control diet
Description: Mixed of different oil
Study NCT02056275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition supplement + dietary counseling
Description: Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
Study NCT02056275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Dietary counseling provided at each study visit by study dietitian.
Study NCT00566709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cells transfusion
Description: Patients will be transfused (one to one red blood cells unit transfusion)
Study NCT00566709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood cells transfusion
Description: Patients will be transfused (one to one red blood cells unit transfusion)
Study NCT03563027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive Gamification
Description: Game-based intervention with points and levels
Study NCT03563027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Sponsor
Description: Participants select a support sponsor to receive weekly updates on progress in the game
Study NCT03563027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT02135874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02135874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00757666 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive pacemaker
Description: Accelerometer sensor
Study NCT00757666 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive pacemaker
Description: Minute ventilation sensor
Study NCT04497324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
Study NCT01882400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Description: Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
Study NCT03679754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: * 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12
Study NCT03679754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veledimex
Description: * 20mg/day~* 15 oral daily doses of veledimex
Study NCT01626378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237
Description: TRx0237 100 mg tablet will be administered twice daily.
Study NCT01626378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Study NCT02052128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone
Study NCT00359437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: oral administration once daily
Study NCT00359437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study NCT01269983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: 8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
Study NCT01269983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Manipulation
Description: 8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy